文献速递冠心病

重组人CD39L3可溶性域联合替格瑞洛在实验性心肌梗死中的心脏保护作用

Recombinant human soluble domain of CD39L3 and ticagrelor: cardioprotective effects in experimental myocardial infarction.
PubMed 文献 · Eur Heart J · 2024-01-01

在替格瑞洛治疗的猪心肌梗死模型中,再灌注前静脉给予AZD3366(solCD39L3)可进一步减少水肿和梗死面积,3 mg/kg剂量较替格瑞洛单药额外降低45%,较对照降低70%(P < .05)。AZD3366还改善左室射血分数和节段收缩功能,且不影响出血时间。

要点

  • 替格瑞洛基础上加用AZD3366可增强心脏保护,减少梗死面积和水肿。
  • 3 mg/kg AZD3366较替格瑞洛单药额外降低45%水肿和梗死面积。
  • AZD3366抑制ADP诱导的血小板聚集但不延长出血时间。

核心结论

  • 在替格瑞洛治疗基础上输注AZD3366可增强心脏保护作用。

研究设计与样本

  • 临床前猪心肌梗死模型:替格瑞洛治疗猪接受球囊诱导MI 90分钟,再灌注前静脉给予vehicle、1 mg/kg或3 mg/kg AZD3366,所有动物替格瑞洛每日两次共42天,另设未治疗MI对照组。

主要发现

  • 替格瑞洛较对照组减少MI后第3天水肿形成和梗死面积。
  • 3 mg/kg AZD3366较替格瑞洛额外降低45%水肿和梗死面积,较对照组降低70%(P < .05)。
  • 第42天,所有替格瑞洛组梗死面积下降,尤其3 mg/kg AZD3366组(P < .05)。
  • 第3天安慰剂组左室射血分数降低且第42天恶化,而替格瑞洛±AZD3366组保持不变。
  • 3 mg/kg AZD3366组第3天多巴酚丁胺负荷时左室射血分数更高,第42天节段收缩功能障碍最小(χ2P < .05 vs 所有组)。

临床怎么用

  • 在替格瑞洛基础上加用AZD3366可能提供额外心脏保护,且不增加出血时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The ecto-nucleoside triphosphate diphosphohydrolases of the CD39 family degrade ATP and ADP into AMP, which is converted into adenosine by the extracellular CD73/ecto-5-nucleotidase. This pathway has been explored in antithrombotic treatments but little in myocardial protection. We have investigated whether the administration of solCD39L3 (AZD3366) confers additional cardioprotection to that of ticagrelor alone in a pre-clinical model of myocardial infarction (MI). METHODS: Ticagrelor-treated pigs underwent balloon-induced MI (90 min) and, before reperfusion, received intravenously either vehicle, 1 mg/kg AZD3366 or 3 mg/kg AZD3366. All animals received ticagrelor twice daily for 42 days. A non-treated MI group was run as a control. Serial cardiac magnetic resonance (baseline, Day 3 and Day 42 post-MI), light transmittance aggregometry, bleeding time, and histological and molecular analyses were performed. RESULTS: Ticagrelor reduced oedema formation and infarct size at Day 3 post-MI vs. controls. A 3 mg/kg AZD3366 provided an additional 45% reduction in oedema and infarct size compared with ticagrelor and a 70% reduction vs. controls (P < .05). At Day 42, infarct size declined in all ticagrelor-administered pigs, particularly in 3 mg/kg AZD3366-treated pigs (P < .05). Left ventricular ejection fraction was diminished at Day 3 in placebo pigs and worsened at Day 42, whereas it remained unaltered in ticagrelor ± AZD3366-administered animals. Pigs administered with 3 mg/kg AZD3366 displayed higher left ventricular ejection fraction upon dobutamine stress at Day 3 and minimal dysfunctional segmental contraction at Day 42 (χ2P < .05 vs. all). Cardiac and systemic molecular readouts supported these benefits. Interestingly, AZD3366 abolished ADP-induced light transmittance aggregometry without affecting bleeding time. CONCLUSIONS: Infusion of AZD3366 on top of ticagrelor leads to enhanced cardioprotection compared with ticagrelor alone.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Vilahur, Radike, Sutelman, et al. Recombinant human soluble domain of CD39L3 and ticagrelor: cardioprotective effects in experimental myocardial infarction. Eur Heart J. 2024. PMID: 38486376. doi:10.1093/eurheartj/ehae107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。